[go: up one dir, main page]

WO1993017040A3 - Cystic fibrosis transmembrane conductance regulator (cftr) protein - Google Patents

Cystic fibrosis transmembrane conductance regulator (cftr) protein Download PDF

Info

Publication number
WO1993017040A3
WO1993017040A3 PCT/CA1993/000065 CA9300065W WO9317040A3 WO 1993017040 A3 WO1993017040 A3 WO 1993017040A3 CA 9300065 W CA9300065 W CA 9300065W WO 9317040 A3 WO9317040 A3 WO 9317040A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
protein
cftr
conductance regulator
transmembrane conductance
Prior art date
Application number
PCT/CA1993/000065
Other languages
French (fr)
Other versions
WO1993017040A2 (en
Inventor
John R Riordan
Christine E Bear
Mohabir Ramjeesingh
Canhui Li
Original Assignee
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Lp filed Critical Hsc Res Dev Lp
Priority to US08/290,935 priority Critical patent/US5543399A/en
Publication of WO1993017040A2 publication Critical patent/WO1993017040A2/en
Publication of WO1993017040A3 publication Critical patent/WO1993017040A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A substantially homogeneous protein having cystic fibrosis transmembrane conductance regulator activity is provided. Also provided is a therapeutically effective composition for treating a subject having cystic fibrosis.
PCT/CA1993/000065 1989-08-22 1993-02-17 Cystic fibrosis transmembrane conductance regulator (cftr) protein WO1993017040A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/290,935 US5543399A (en) 1989-08-22 1993-02-17 Cystic fibrosis transmembrane conductance regulator (CFTR) protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,061,579 1992-02-20
CA 2061579 CA2061579C (en) 1992-02-20 1992-02-20 Cystic fibrosis transmembrane conductance regulator (cftr) protein

Publications (2)

Publication Number Publication Date
WO1993017040A2 WO1993017040A2 (en) 1993-09-02
WO1993017040A3 true WO1993017040A3 (en) 1993-09-30

Family

ID=4149304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000065 WO1993017040A2 (en) 1989-08-22 1993-02-17 Cystic fibrosis transmembrane conductance regulator (cftr) protein

Country Status (3)

Country Link
AU (1) AU3489193A (en)
CA (1) CA2061579C (en)
WO (1) WO1993017040A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984487B1 (en) 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
US6063913A (en) * 1989-08-22 2000-05-16 Hsc Research And Development Limited Partnership Stable heterologous propagation CFTR protein variant cDNA
AU7060591A (en) * 1990-01-12 1991-08-05 Hsc Research Development Corporation Introns and exons of the cystic fibrosis gene and mutations at various positions of the gene
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0446017A1 (en) * 1990-03-05 1991-09-11 Genzyme Corporation New diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0446017A1 (en) * 1990-03-05 1991-09-11 Genzyme Corporation New diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL. vol. 64, no. 4, 22 February 1991, CAMBRIDGE, MA, US pages 681 - 691 N. KARTNER ET AL. 'EXPRESSION OF THE CYSTIC FIBROSIS GENE IN NON-EPITHELIAL INVERTEBRATE CELLS PRODUCES A REGULATED ANION CONDUCTANCE.' cited in the application *
CELL. vol. 68, no. 4, 21 February 1992, CAMBRIDGE, MA, US pages 809 - 818 C.E. BEAR ET AL. 'PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR ( CFTR ).' *

Also Published As

Publication number Publication date
CA2061579C (en) 2008-07-22
WO1993017040A2 (en) 1993-09-02
CA2061579A1 (en) 1993-08-21
AU3489193A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
AU1912897A (en) Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
AU7128196A (en) Synergistically active herbicidal mixtures
AU4308789A (en) Active roll control system
AU4180693A (en) Foam control agents
AU3592897A (en) Toxins active against pests
AU2024195A (en) Coherence optimized active adaptive control system
AU7157896A (en) Cystic fibrosis therapy
AU3190593A (en) Molecules for iontophoretic delivery
AU2270695A (en) Active compounds
AU2767697A (en) Process and agents for controlling harmful fungi
WO1993017040A3 (en) Cystic fibrosis transmembrane conductance regulator (cftr) protein
HRP960375B1 (en) Therapeutically active compounds
AU4314993A (en) Mixtures of active anti-microbial substances
AU6124496A (en) Combinations of active fungicidal agents
AU5538794A (en) Biologically active compounds and process therefor
GB9216962D0 (en) Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives
AU1952292A (en) Applicator for biologically active substance
AU5573994A (en) Wood impregnation process
AU4981693A (en) Optically active carboxamide derivative
AU4971893A (en) Adjusting moisture regain
AU1093697A (en) Active bio-compounds
AU1804092A (en) Floor treating machine
AU4701893A (en) 2-arylhydrazono-3-ketonic acid piperidides as pest control agents
AU7630694A (en) Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
AU7952194A (en) Butt reducing machine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU FI JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU FI JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08290935

Country of ref document: US

122 Ep: pct application non-entry in european phase